麗珠集團(000513.SZ):單抗新藥臨牀試驗申請獲受理
格隆匯2月21日丨麗珠集團(000513.SZ)公佈,近日,公司控股附屬公司麗珠單抗申報的“注射用重組腫瘤酶特異性干擾素α-2bFc融合蛋白”(下稱“A-01”)臨牀試驗申請獲國家藥品監督管理局受理。
A-01為全球創新藥物,旨在開發一種長效靶向性細胞因子前體藥物,該藥物進入人體後在人體的外周循環系統和正常組織中主要以前體藥物形式存在,當該前體藥物進入到腫瘤組織後,暴露藥物活性成分,從而在特定腫瘤部位發揮特異性抗腫瘤效應。另外,通過與抗體IgGFc融合,延長了該前體藥物在人體內的半衰期。
截至目前,麗珠單抗在A-01研發項目上已累計投入人民幣3225.64萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.